Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - September 2013


Your body is 3D, why is your cell culture not?

27 Sep 2013 - 27 Sep 2013 - Webinar



Bookmark and Share


3D cell-based applications close the gap between conventional in-vitro approaches and in vivo animal model research. By automating the 3D cell culture process and assay detection in a microplate based format, this significantly shortens development time of new drug candidates as well as offering more reliable statistical results.   

Tecan will present solutions for 3D cell culture systems using the Alvetex (Reinnervate), RAFT (TAP Biosystems)  scaffold based, and GravityPlus (InSphero) scaffold-free technology. In particular, automating a 3D cell culture system with the Freedom EVO® liquid handling platform offers a simple and reliable approach for cultivation, and the Infinite M-200 PRO multi-detection reader with its Optimal Read function in conjunction with the patent pending Gas Control Module (GCMTM) offers an excellent solution for acute and chronic toxicity tests, as well as multiplexed assays in cancer research.

Presenter:
Christian Oberdanner, PhD
Application Specialist Sales & Marketing, Tecan Austria GmbH

Christian Oberdanner, PhD, studied Molecular- and Cell-Biology at the University of Salzburg, Austria. In his doctoral thesis he focused on Reactive Oxygen Species-mediated apoptosis induction in photodynamic cancer therapy. 

Christian started to work for Tecan Austria as an external scientific consultant already during his last year at University. After his graduation he joined Tecan as Application Specialist in the department for research and development but quickly changed to the sales and marketing department. His expertise is on applications for Tecan’s multimode readers and microplate washers but he is also contributing to new product developments as a Junior Product Manager.


Further information
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Computerized Flexible Needles Prove Themselves in Biological Tissue
The advantage of the system is that you can avoid obstacles with the needles or critical tissues and that the system during the insertion of the needle in real time can adjust the path if, for example, the tissue deforms.
DARWIN 2 24-week Monotherapy Data in RA Confirm Previous Results
Safety profile in DARWIN 2 consistent with previous filgotinib RA studies.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Overdose of Vitamin D in Teenagers May Lead to Increased Cholesterol Levels
Dosing obese teens with vitamin D shows no benefits for their heart health or diabetes risk, and could have the unintended consequences of increasing cholesterol and fat-storing triglycerides. These are the latest findings in a series of Mayo Clinic studies in childhood obesity.
Phase 2 Trials Underway for New Single Dose Malaria Treatment
The new drug, which prevents the malaria parasite from reproducing and spreading, is now undergoing Phase II clinical trials in humans.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!